Related Experiment Video

Updated: Aug 2, 2025

Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
10:13

Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding

Published on: June 9, 2017

16.5K

How can we improve the measurement of receptor signaling bias?

Karim Nagi1

  • 1College of Medicine, QU Health, Qatar University, Doha, Qatar.

Expert Opinion on Drug Discovery
|April 19, 2023
PubMed
Abstract

No abstract available in PubMed .

Keywords:
Biased agonismBiased ligandDrug discoveryFunctional selectivityGPCRReceptor signalingScreeningSignaling biasSignaling pathways

More Related Videos

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.3K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

12.7K

Related Experiment Videos

Last Updated: Aug 2, 2025

Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
10:13

Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding

Published on: June 9, 2017

16.5K
Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

19.3K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

12.7K

Related Concept Videos

The Two-State Receptor Model01:29

The Two-State Receptor Model

2.0K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
2.0K

Articles linked to this work by shared authors, journal, and citation graph.

Global Prevalence and Cancer Risk of Epstein-Barr Virus and Human Papillomavirus Coinfection in Breast Cancer: A Systematic Review and Meta-Analysis.

Viruses·2025

USP20 deletion promotes eccentric cardiac remodeling in response to pressure overload and increases mortality.

American journal of physiology. Heart and circulatory physiology·2024

Comprehensive Signaling Profiles Reveal Unsuspected Functional Selectivity of δ-Opioid Receptor Agonists and Allow the Identification of Ligands with the Greatest Potential for Inducing Cyclase Superactivation.

ACS pharmacology & translational science·2021

Copresence of High-Risk Human Papillomaviruses and Epstein-Barr Virus in Colorectal Cancer: A Tissue Microarray and Molecular Study from Lebanon.

International journal of molecular sciences·2021

High-risk human papillomaviruses and Epstein-Barr virus in breast cancer in Lebanese women and their association with tumor grade: a molecular and tissue microarray study.

Cancer cell international·2021

Author Correction: Exploring use of unsupervised clustering to associate signaling profiles of GPCR ligands to clinical response.

Nature communications·2020

Organoids in drug discovery and development: emerging technologies to transition beyond animal models.

Expert opinion on drug discovery·2026

Using molecular modeling and QSAR-based design strategies for advancing the development of therapeutic solute carrier 6 (SLC6) transporter ligands.

Expert opinion on drug discovery·2026

Lymph node models of chronic lymphocytic leukemia for translational evaluation of new drug candidates.

Expert opinion on drug discovery·2026

Strategy-based design for the identification of next generation β-lactam antibiotics that evade resistance from Gram-negative pathogens.

Expert opinion on drug discovery·2026

Design considerations for in silico drug discovery platform that can accelerate targeted drug repurposing: a focus on rare, neglected, and emerging diseases.

Expert opinion on drug discovery·2026

The rapid emergence of small molecule RNA modulator hit discovery: unlocking the potential.

Expert opinion on drug discovery·2026

The effect of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors on stroke risk in type 2 diabetes: a nationwide longitudinal cohort study in Sweden with contextualisation analysis.

EClinicalMedicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us